Cargando…
In Vitro Diffuse Large B-Cell Lymphoma Cell Line Models as Tools to Investigate Novel Immunotherapeutic Strategies
SIMPLE SUMMARY: Despite a range of emerging immunotherapeutic strategies, the aggressive nature of DLBCL poses an ongoing clinical challenge. Therefore, there is a need to pursue more effective treatment modalities based on monoclonal antibodies, antibody-drug conjugates and CAR-T cell therapy. Up t...
Autores principales: | Kubacz, Matylda, Kusowska, Aleksandra, Winiarska, Magdalena, Bobrowicz, Małgorzata |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9818372/ https://www.ncbi.nlm.nih.gov/pubmed/36612228 http://dx.doi.org/10.3390/cancers15010235 |
Ejemplares similares
-
Molecular Aspects of Resistance to Immunotherapies—Advances in Understanding and Management of Diffuse Large B-Cell Lymphoma
por: Kusowska, Aleksandra, et al.
Publicado: (2022) -
The “Magic Bullet” Is Here? Cell-Based Immunotherapies for Hematological Malignancies in the Twilight of the Chemotherapy Era
por: Miazek-Zapala, Nina, et al.
Publicado: (2021) -
CD37 in B Cell Derived Tumors—More than Just a Docking Point for Monoclonal Antibodies
por: Bobrowicz, Malgorzata, et al.
Publicado: (2020) -
P611: CD37 AS A MOLECULAR TARGET FOR CAR-T CELLS AGAINST CHRONIC LYMPHOCYTIC LEUKEMIA
por: Kusowska, Aleksandra, et al.
Publicado: (2023) -
Selective inhibition of HDAC6 sensitizes cutaneous T-cell lymphoma to PI3K inhibitors
por: Bobrowicz, Malgorzata, et al.
Publicado: (2020)